Literature DB >> 3029566

Factors influencing alternative splice site utilization in vivo.

X Y Fu, J L Manley.   

Abstract

To study factors that influence the choice of alternative pre-mRNA splicing pathways, we introduced plasmids expressing either wild-type or mutated simian virus 40 (SV40) early regions into tissue culture cells and then measured the quantities of small-t and large-T RNAs produced. One important element controlling splice site selection was found to be the size of the intron removed in the production of small-t mRNA; expansion of this intron (from 66 to 77 or more nucleotides) resulted in a substantial increase in the amount of small-t mRNA produced relative to large-T mRNA. This suggests that in the normal course of SV40 early pre-mRNA processing, large-T splicing is at a competitive advantage relative to small-t splicing because of the small size of the latter intron. Several additional features of the pre-mRNA that can influence splice site selection were also identified by analyzing the effects of mutations containing splice site duplications. These include the strengths of competing 5' splice sites and the relative positions of splice sites in the pre-mRNA. Finally, we showed that the ratio of small-t to large-T mRNA was 10 to 15-fold greater in human 293 cells than in HeLa cells or other mammalian cell types. These results suggest the existence of cell-specific trans-acting factors that can dramatically alter the pattern of splice site selection in a pre-mRNA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029566      PMCID: PMC365130          DOI: 10.1128/mcb.7.2.738-748.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Processing and expression of early SV40 mRNA: a role for RNA conformation in splicing.

Authors:  G Khoury; P Gruss; R Dhar; C J Lai
Journal:  Cell       Date:  1979-09       Impact factor: 41.582

2.  Intricate combinatorial patterns of exon splicing generate multiple regulated troponin T isoforms from a single gene.

Authors:  R E Breitbart; H T Nguyen; R M Medford; A T Destree; V Mahdavi; B Nadal-Ginard
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

3.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

4.  A single mouse alpha-amylase gene specifies two different tissue-specific mRNAs.

Authors:  R A Young; O Hagenbüchle; U Schibler
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

5.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

6.  Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways.

Authors:  P Early; J Rogers; M Davis; K Calame; M Bond; R Wall; L Hood
Journal:  Cell       Date:  1980-06       Impact factor: 41.582

7.  The role of DNA rearrangement and alternative RNA processing in the expression of immunoglobulin delta genes.

Authors:  R Maki; W Roeder; A Traunecker; C Sidman; M Wabl; W Raschke; S Tonegawa
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

8.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

9.  Regulation of adenovirus-2 gene expression at the level of transcriptional termination and RNA processing.

Authors:  J R Nevins; M C Wilson
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

10.  DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells.

Authors:  M Wigler; A Pellicer; S Silverstein; R Axel; G Urlaub; L Chasin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

View more
  54 in total

1.  Sequences upstream of the branch site are required to form helix II between U2 and U6 snRNA in a trans-splicing reaction.

Authors:  G Ast; T Pavelitz; A M Weiner
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

2.  cis-acting sequences involved in exon selection in the chicken beta-tropomyosin gene.

Authors:  M E Gallego; L Balvay; E Brody
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

3.  Multiple functional domains of human U2 small nuclear RNA: strengthening conserved stem I can block splicing.

Authors:  J Wu; J L Manley
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

4.  Multiple activities of the human splicing factor ASF.

Authors:  J E Harper; J L Manley
Journal:  Gene Expr       Date:  1992

5.  Sequences involved in the control of adenovirus L1 alternative RNA splicing.

Authors:  J P Kreivi; K Zerivitz; G Akusjärvi
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

6.  The late spliced 19S and 16S RNAs of simian virus 40 can be synthesized from a common pool of transcripts.

Authors:  P J Good; R C Welch; W S Ryu; J E Mertz
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

7.  The simian virus 40 small-t intron, present in many common expression vectors, leads to aberrant splicing.

Authors:  M T Huang; C M Gorman
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

8.  cis-acting elements and a trans-acting factor affecting alternative splicing of adenovirus L1 transcripts.

Authors:  C Delsert; N Morin; D F Klessig
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

9.  Oligonucleotide-targeted degradation of U1 and U2 snRNAs reveals differential interactions of simian virus 40 pre-mRNAs with snRNPs.

Authors:  Z Q Pan; H Ge; X Y Fu; J L Manley; C Prives
Journal:  Nucleic Acids Res       Date:  1989-08-25       Impact factor: 16.971

10.  Splice site selection in polyomavirus late pre-mRNA processing.

Authors:  D B Batt; L M Rapp; G G Carmichael
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.